The impact of camostat mesilate on COVID-19

The Department of Clinical Pharmacology is in a collaboration with the Department of Infectious diseases at Aarhus University Hospital involved in a protocol investigating the use of camostat mesilate in the treatment of COVID19.

The protocol titled “The Impact of Camostat Mesilate on COVID-19 Infection: An investigator-initiated randomized, placebo-controlled, phase IIa trial (CamoCO-19)” is a randomized, placebo-controlled, double-blinded national multicenter interventional phase IIa trial designed to evaluate the safety and efficacy of Camostat Mesilate as intervention to reduce morbidity and mortality in patients with documented or suspected COVID-19 infection.

Read more on,clinical trial number NCT04321096

Or here: